Lupus
3 years 2 months ago
#ACR21 Ab#1029 - Great poster by Dr. Guttmann, IRAD in Summit NJ:
▶️2019 EULAR/ACR SLE criteria vs to 1997 ACR & SLICC
⭐️64% SLE pts: all 3 criteria. 10% only SLICC, 3% '97 ACR, 2% EULAR/ACR
⭐️Simliar gender, racial disparities to prior criteria
@Rheumnow https://t.co/QzG78HJgw5 https://t.co/eyuYhj4Acf
3 years 2 months ago
#ACR21 Abst#1029 @Rheumnow https://t.co/QzG78HJgw5
What is your preferred SLE classification criteria?
3 years 2 months ago
#ACR21 Abs:#1429: ALPN-303: Dual BAFF/APRIL antagonist for SLE:
⭐️Encouraging immunomodulatory activity and efficacy in animal models. ⬇️ Plasma cells and Ig secretions in vitro & vivo
⭐️Well-tolerated in animals w/o adverse events
🔥Phase 1 study in healthy volunteers!
@Rheumnow
3 years 2 months ago
#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC:
⬇️Titres of Abs in SLE vs controls
💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA
📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9
3 years 2 months ago
📢#ACR21 #Abstr1421 Is #COVID19 vaccine safe and effective in #lupus? YES!! VOCOLUP study (N=1189 pts) showed:
💠~45% had a side-effect; of which 80% mild/moderate
💠Only 3% flared post💉(MSK + Fatigue); 10 required hospitalisation @RheumNow #ACRBest https://t.co/WF4aAfiX70 https://t.co/jc0HQoJymo
3 years 2 months ago
Young patients with #SLE #lupus have a #multimorbidity burden similar to individuals 30years older than them.
A high #comorbidity burden is present in SLE pts of all ages compared to non-SLE.
How can we address this?
Abs#1049 #ACR21 #ACRBest @RheumNow
https://t.co/U6t8YBFUZz https://t.co/v7Fwof1gZc
3 years 2 months ago
Watch: Lupus Updates: Dr. Michelle Petri
Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting.
https://t.co/L7T2mNJVH0 https://t.co/MCQ7nJjCIY